These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 11795080

  • 21. Cardiovascular effects of raloxifene: the arterial and venous systems.
    Blumenthal RS, Baranowski B, Dowsett SA.
    Am Heart J; 2004 May; 147(5):783-9. PubMed ID: 15131531
    [Abstract] [Full Text] [Related]

  • 22. New developments in postmenopausal hormone replacement therapy.
    Prelevic GM, Jacobs HS.
    Curr Opin Obstet Gynecol; 1997 Jun; 9(3):207-12. PubMed ID: 9263706
    [Abstract] [Full Text] [Related]

  • 23. Selective estrogen-receptor modulators for primary prevention of breast cancer.
    Fabian CJ, Kimler BF.
    J Clin Oncol; 2005 Mar 10; 23(8):1644-55. PubMed ID: 15755972
    [No Abstract] [Full Text] [Related]

  • 24. Letter by Choi et al regarding article, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors".
    Choi BG, Vilahur G, Badimon JJ.
    Circulation; 2009 Oct 27; 120(17):e147; author reply e148. PubMed ID: 19858421
    [No Abstract] [Full Text] [Related]

  • 25. [Primary prevention of cardiovascular diseases by lowering lipids].
    Klose G.
    Internist (Berl); 1997 Jun 27; 38(6):615-6. PubMed ID: 9265009
    [No Abstract] [Full Text] [Related]

  • 26. Cardiovascular disease and hormone replacement therapy in post-menopausal women.
    Rapeport N.
    Cardiovasc J S Afr; 2005 Jun 27; 16(2):76-80. PubMed ID: 15915271
    [No Abstract] [Full Text] [Related]

  • 27. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC, Lien YR, Chen M, Cheng SP, Chen RJ, Chow SN.
    Acta Obstet Gynecol Scand; 2004 Jul 27; 83(7):661-6. PubMed ID: 15225192
    [Abstract] [Full Text] [Related]

  • 28. Gynecologists and estrogen: an affair of the heart.
    Fugh-Berman A, Scialli AR.
    Perspect Biol Med; 2006 Jul 27; 49(1):115-30. PubMed ID: 16489281
    [Abstract] [Full Text] [Related]

  • 29. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy?
    Beck V, Rohr U, Jungbauer A.
    J Steroid Biochem Mol Biol; 2005 Apr 27; 94(5):499-518. PubMed ID: 15876415
    [Abstract] [Full Text] [Related]

  • 30. [Hormone replacement therapy and cardiovascular prevention: many statements, some doubts].
    Motolese M.
    Ital Heart J Suppl; 2003 Jul 27; 4(7):545-58. PubMed ID: 14558283
    [Abstract] [Full Text] [Related]

  • 31. Raloxifene for the treatment and prevention of breast cancer?
    Pappas SG, Jordan VC.
    Expert Rev Anticancer Ther; 2001 Oct 27; 1(3):334-40. PubMed ID: 12113100
    [Abstract] [Full Text] [Related]

  • 32. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F, Marziani R, Perniola G, Ebano V, Fruscella M, Mossa B.
    Minerva Ginecol; 2003 Feb 27; 55(1):87-93. PubMed ID: 12598849
    [Abstract] [Full Text] [Related]

  • 33. [Selective estrogen receptor modulators].
    Palacios Gil-Antuñano S, Cifuentes Otero I, Menéndez Ceño C.
    Rev Clin Esp; 1999 Oct 27; 199(10):670-4. PubMed ID: 10589254
    [No Abstract] [Full Text] [Related]

  • 34. [Postmenopausal estrogen replacement therapy and the risk of atherosclerotic cardiovascular diseases].
    Donders SH.
    Ned Tijdschr Geneeskd; 1992 Jul 25; 136(30):1478. PubMed ID: 1436167
    [No Abstract] [Full Text] [Related]

  • 35. Be careful of what you wish for: putting the WHI Estrogen/Progestin and HERS II Trials in perspective.
    Randolph JF, Women's Health Initiative Estrogen/Progestin and HERS II Trials.
    Medscape Womens Health; 2002 Jul 25; 7(4):7. PubMed ID: 12466739
    [No Abstract] [Full Text] [Related]

  • 36. [Hormone replacement therapy and cardiovascular prevention. Where are we now?].
    Lerman J, Siseles N.
    Medicina (B Aires); 2008 Jul 25; 68(3):251-7. PubMed ID: 18689159
    [Abstract] [Full Text] [Related]

  • 37. [Effects of estrogens and progestogens on the lipid profile in postmenopausal hypogonadism].
    García L, Hernández I, Cervera Aguilar R, Ayala AR.
    Ginecol Obstet Mex; 2001 Sep 25; 69():351-4. PubMed ID: 11816532
    [Abstract] [Full Text] [Related]

  • 38. Postmenopausal hormone therapy: the way ahead.
    Pines A.
    Maturitas; 2007 May 20; 57(1):3-5. PubMed ID: 17376615
    [Abstract] [Full Text] [Related]

  • 39. [Postmenopausal hormone replacement therapy and cardiovascular disease].
    Høibraaten E.
    Tidsskr Nor Laegeforen; 2002 Jun 20; 122(16):1564-5. PubMed ID: 12119783
    [No Abstract] [Full Text] [Related]

  • 40. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
    Gandhi S, Verma S.
    Breast Cancer Res Treat; 2007 Nov 20; 106(1):1-9. PubMed ID: 17211535
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.